Topics
CME/CE
Editorial Board
Expanding Possibilities
San Francisco - The expanding indications for the topical immune response modulator imiquimod (Aldara) may soon include treatment of superficial basal cell carcinoma (BCC), Mark Naylor, M.D., said at the annual meeting of the American Academy of Dermatology.
Related Videos
Related Content
